About Amferia
Amferia is a Healthcare company based in Goteborg (Sweden) founded in 2018 by Anand Kumar Rajasekharan and Saba Atefyekta. It operates as an anti-infective technology is developed using selective anti-bacterial polymers. Amferia has raised $7.56 million across 6 funding rounds from investors including European Union, Chalmers Ventures and Almi. Its chief executive is Anand Kumar Rajasekharan. Amferia offers products and services including Antimicrobial Hydrogel Dressing, Antimicrobial Sprays, and Antibacterial Coatings. Its focus areas include Life Sciences, Infectious Diseases, Medical Devices and Therapeutics. Its legal entity is Amferia AB. Its competitors include Cerus, Aethlon Medical, Ondine Biomedical, Larada Sciences and 3Oe Scientific and 3 more; 4 of its 8 listed competitors have raised funding.
Company details
Amferia was founded in 2018 in Gothenburg, Sweden, within the biotechnology sector. Proprietary anti-bacterial polymers are being developed by the company to target and eliminate bacteria, including those resistant to antibiotics. The technology is designed to be selective, affecting only bacterial cells while remaining non-toxic to human cells. Operations focus on advancing this patented material for potential applications in infection control.
- Headquarters Goteborg, Sweden
- Founders Anand Kumar Rajasekharan, Saba Atefyekta
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website amferia.com
- Social LinkedIn
- Legal Name Amferia Ab
- Total Equity Funding$7.56M (USD)
in 6 rounds
- Latest Funding Round$4.11M (USD), Series B
Dec 2025
- InvestorsEuropean Union
& 6 more
Products & Services of Amferia
Amferia offers a comprehensive portfolio of products and services, including Antimicrobial Hydrogel Dressing, Antimicrobial Sprays, and Antibacterial Coatings.
Hydrogel that kills bacteria using peptides for safe healing.
Sprays to prevent infections in medical procedures.
Coatings for devices to resist bacterial growth.
Funding Insights of Amferia
Amferia has successfully raised a total of $7.56M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $4.11 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.56M
- Total Rounds 6
- Last Round Series B — $4.11M
- First Round $54,958
(Sep 2019)
- Investors Count 7
All 6 funding rounds of Amferia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $4.11M | Series B | – | – | – |
| Sep 2024 | $1.33M | Series A | – | Chalmers Ventures | – |
| Jan 2023 | $1.47M | Series A | – | Almi | |
| Feb 2020 | $55,020 | Grant | – | – | |
| Jan 2020 | $650,000 | Seed | – | Corinthian Property Management, Almi Invest | |
| Sep 2019 | $54,958 | Grant | – | – |
7 investors in total: 6 institutional and 1 angel.
Investors in Amferia
Amferia has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, Chalmers Ventures and Almi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage investments are made across sectors in Europe. | 2015 | chalmersventures.com | Gothenburg, Sweden | |
Investments are provided by Almi in seed to growth-stage startups. | 1994 | almi.se | Stockholm, Sweden | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Multiple sectors are invested in by corporate-backed Almi Invest. | – | almi.se/Almi-Invest/ | Lund, Sweden | |
- | – | corinthian.co.nz | - | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
AH Alexander Hars | - | – | unknown_1f40d27258f943c0a | - |
Investor details for Amferia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amferia
5 people are tracked at Amferia (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Anand Kumar Rajasekharan | Co-Founder & CEO | Leadership |
Saba Atefyekta | Co-Founder | Leadership |
Daniel Hagberg | CTO | Leadership |
Peter Andersson | Director Of Partnerships | Leadership |
Edvin Blomstrand | R&D Engineer | Team |
Complete people profiles for Amferia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Amferia
3 dated milestones of Amferia across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Amferia is founded.
- Funding First funding round of $55K.
- Funding Latest funding round, Series B, of $4.1M.
Competitors of Amferia
Amferia has 8 listed competitors in our database, 4 of them funded. They include Cerus, Aethlon Medical, Ondine Biomedical, Larada Sciences and 3Oe Scientific, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cerus.com | 1991 | Concord, United States | – | 247 | Provider of pathogen inactivation technology for blood center or hospital blood bank | |
| aethlonmedical.com | 1999 | San Diego, United States | – | 14 | Hemopurification devices are developed to eliminate viruses and exosomes. | |
| ondinebio.com | 1999 | Vancouver, Canada | – | 49 | Anti-infective therapies are developed via light-activated Photodisinfection technology. | |
| laradasciences.com | 2006 | Salt Lake, United States | $2.63M | – | Head lice are removed by a network of certified professionals. | |
| 3oescientific.com | 2010 | Carmel, United States | $3.71M | – | Provider of smart solutions to manage pathogen infections | |
| toefx.com | 2016 | Hamilton, Canada | $30,000 | – | Treatments for toenail fungus are developed using photodynamic therapy. | |
| zappkit.com | 2007 | Hafnarfjordur, Iceland | – | – | Provides frequency therapy through mobile app and hardware for user health support. | |
| pathex.co | 2016 | Nashville, United States | $5M | – | Developing blood-cleansing device to remove pathogens from circulating blood |
Detailed competitors of Amferia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as Amferia (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amferia
Complete news archive for Amferia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amferia
Amferia was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Amferia is headquartered in Goteborg, Sweden. It is registered at Goteborg, Vastra Gotaland, Sweden.
Anand Kumar Rajasekharan is the current CEO of Amferia. They have also founded this company.
Amferia is a funded company, having raised a total of $7.56M across 6 funding rounds to date. The company's 1st funding round was a Grant of $54.96K, raised on Sep 2019.
Amferia was founded in 2018 in Gothenburg, Sweden, within the biotechnology sector. Proprietary anti-bacterial polymers are being developed by the company to target and eliminate bacteria, including those resistant to antibiotics. The technology is designed to be selective, affecting only bacterial cells while remaining non-toxic to human cells. Operations focus on advancing this patented material for potential applications in infection control.
Amferia's top competitors include Cerus, Aethlon Medical and PATH EX.
Amferia offers Antimicrobial Hydrogel Dressing, Antimicrobial Sprays, and Antibacterial Coatings.
Amferia has 7 investors. Key investors include European Union, Chalmers Ventures, Almi, EIC Fund, and Corinthian Property Management.
Amferia operates through Amferia Ab.